110 related articles for article (PubMed ID: 2504680)
41. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
43. Preclinical studies with prothymosin alpha1 on mononuclear cells from tumor patients.
Eckert K; Grünberg E; Garbin F; Maurer HR
Int J Immunopharmacol; 1997; 19(9-10):493-500. PubMed ID: 9637344
[TBL] [Abstract][Full Text] [Related]
44. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin.
Basu S; Sodhi A; Singh SM; Suresh A
Immunol Lett; 1991 Mar; 27(3):199-204. PubMed ID: 2060971
[TBL] [Abstract][Full Text] [Related]
45. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
46. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
47. A functional and phenotypic comparison of murine natural killer (NK) cells and lymphokine-activated killer (LAK) cells.
Hoskin DW; Stankova J; Anderson SK; Roder JC
Int J Cancer; 1989 May; 43(5):940-8. PubMed ID: 2469657
[TBL] [Abstract][Full Text] [Related]
48. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
Koberda J; Bergmann L; Mitrou PS; Hoelzer D
J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
[TBL] [Abstract][Full Text] [Related]
49. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
50. Lower concentrations of methyl-β-cyclodextrin combined with interleukin-2 can preferentially induce activation and proliferation of natural killer cells in human peripheral blood.
Lü HZ; Zhu AY; Chen Y; Tang J; Li BQ
Hum Immunol; 2011 Jul; 72(7):538-46. PubMed ID: 21540068
[TBL] [Abstract][Full Text] [Related]
51. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
52. Effect of lymphokine-activated killer cells on human retinoblastoma cells (Y-79) in vitro: enhancement of the activity by a polysaccharide preparation, krestin.
Hayashida Y; Kurimoto S; Yamamoto N
Biochem Biophys Res Commun; 1991 Jan; 174(1):107-14. PubMed ID: 1899189
[TBL] [Abstract][Full Text] [Related]
53. Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.
Klimpel GR; Herndon DH; Stein MD
J Clin Immunol; 1988 Jan; 8(1):14-22. PubMed ID: 2966807
[TBL] [Abstract][Full Text] [Related]
54. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
55. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
56. Natural killer and natural killer-like cell activity of peripheral blood and intrathyroidal mononuclear cells from patients with Graves' disease.
Tezuka H; Eguchi K; Fukuda T; Otsubo T; Kawabe Y; Ueki Y; Matsunaga M; Shimomura C; Nakao H; Ishikawa N
J Clin Endocrinol Metab; 1988 Apr; 66(4):702-7. PubMed ID: 3257969
[TBL] [Abstract][Full Text] [Related]
57. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.
Grönberg A; Ferm M; Tsai L; Kiessling R
Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094
[TBL] [Abstract][Full Text] [Related]
58. Effects of diheptyldiselenide (DDS) on human tumor cell lines and on peripheral blood mononuclear cells.
Tentori L; Prete SP; Pepponi R
J Chemother; 1993 Oct; 5(5):325-33. PubMed ID: 8106907
[TBL] [Abstract][Full Text] [Related]
59. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
60. [The effect of corticosteroid on lymphokine-activated killer (LAK) activity and the change of membrane antigen phenotype on PBMC after IL2 incubation with reference to the evaluation in vitro].
Yoshimura A
Nihon Ika Daigaku Zasshi; 1990 Jun; 57(3):211-21. PubMed ID: 2376610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
